The trial evaluates survival outcomes for recurrent head and neck squamous cell carcinoma post-radiation therapy, comparing ...

Deferring systemic therapy may improve survival outcomes in carefully selected patients with metastatic renal cell carcinoma, new data suggest.

Serial metastasis-directed radiotherapy extended time off systemic therapy while maintaining favorable progression-free and overall survival in patients with oligometastatic clear-cell renal cell ...

Overall, the “Hidradenitis Suppuritiva Update 2026” session underscored a new treatment paradigm: HS care in 2026 requires early diagnosis, systemic screening, combination medical therapy, and ...

The results of this study highlight the need for more research into how treatment at the end of life is shaped by oncologists’ unique treatment propensities, according to researchers. Oncologists’ ...

(RTTNews) - Citius Oncology, Inc. (CTOR), the oncology subsidiary of Citius Pharmaceuticals Inc. (CTXR) announced the U.S. commercial launch of LYMPHIR, a new immunotherapy for adults with relapsed or ...